Pharmacokinetic (PK) and Pharmacodynamic (PD) Studies of RUC-4 Succinate, a Novel αIIbβ3 Pure Antagonist for First Point of Contact Treatment of ST Segment Elevated Myocardial Infarction (STEMI)

Document Type

Abstract

Publication Date

11-29-2018

Publication Title

Blood

DOI

10.1182/blood-2018-99-112233

This document is currently not available here.

Share

COinS